Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
61,842.32 +2,590.46 (+4.37%) CMC Crypto 200
1,342.55 +65.58 (+5.13%)
Galecto, Inc. (GLTO)
| Previous close | 0.7106 |
| Open | 0.7308 |
| Bid | 0.6758 x 100 |
| Ask | 0.7409 x 100 |
| Day's range | 0.7000 - 0.7399 |
| 52-week range | 0.5000 - 3.7000 |
| Volume | |
| Avg. volume | 213,072 |
| Market cap | 19.063M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4400 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
GlobeNewswireGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinomaBOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for ca
ZacksGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksWhat Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
